Experienced in Scleroderma

Andreas Schwarting

Kaiser Wilhelm Str. 9-11, 
Bad Kreuznach, RP, DE 
Experienced in Scleroderma
Kaiser Wilhelm Str. 9-11, 
Bad Kreuznach, RP, DE 
OverviewLocationsClinical Research

Overview

Andreas Schwarting practices in Bad Kreuznach, Germany. Mr. Schwarting is rated as an Experienced expert by MediFind in the treatment of Scleroderma. His top areas of expertise are Antisynthetase Syndrome, Systemic Lupus Erythematosus (SLE), Arthritis, and Myositis.

His clinical research consists of co-authoring 133 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Scleroderma.

Gender
Male

Locations

Kaiser Wilhelm Str. 9-11, Bad Kreuznach, RP 55543, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 2 Less Clinical Trials

133 Total Publications

From renal crisis to lung fibrosis - systemic sclerosis in the course of time
From renal crisis to lung fibrosis - systemic sclerosis in the course of time
Journal: Deutsche medizinische Wochenschrift (1946)
Published: August 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schwarting's expertise for a condition
ConditionClose
View All 40 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile